Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Casebia Therapeutics

www.casebia.com

Latest From Casebia Therapeutics

Pyxis Oncology: New Routes To Immuno-Oncology Therapies

Bayer’s VC LEAPS program invests in a second new biotech this month through its participation in the series A funding round for new immuno-oncology biotech Pyxis Oncology.

 

Financing ImmunoOncology

Versant's Century Aims For Off-The-Shelf Cancer Cell Therapies

With Bayer’s venture arm providing $215m, Versant Ventures’ Century Therapeutics emerges with $250m and a plan to develop allogeneic stem cell therapies for various cancers, including solid tumors.

ImmunoOncology Business Strategies

Finance Watch: A One-Time Treatment For Heart Disease? Verve Raises $58.5m To Give It A Try

Private Company Edition: With academic muscle, Google cash and nanoparticles, and various CRISPR licenses, Verve will develop gene-editing therapies for coronary heart disease prevention. Also, Vividion raises an $82m series B and two Belgian companies bring in $77.8m in VC cash.

Financing StartUps and SMEs

Casebia Counts On Collaboration In Its Climb To Leadership In Gene Therapy

Casebia Therapeutics, a three-year old start-up in the hotly contested gene therapy space, is the product of a remarkably relaxed joint venture between the German multinational giant Bayer and CRISPR Therapeutics, a leader in conducting the first clinical trial involving the CRISPR-Cas9 editing platform. 

C-Suite Speaks Leadership
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Cardiovascular
  • Immune Disorders
  • Ophthalmic
  • Alias(es)
  • Bayer-CRISPR JV
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Casebia Therapeutics
  • Senior Management
  • James W Burns, PhD, Pres. & CEO
    Peter Nell, MD, VP, Strategy & Bus. Dev.
    Paul Schneider, VP, Fin.
  • Contact Info
  • Casebia Therapeutics
    Phone: (857) 270-5100
    610 Main St. N.
    5th Fl.
    Cambridge, MA 02139
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register